AC Immune adds director Graney’s power of attorney
The director's reported options cover 19,565 common shares, are exercisable June 10, 2027, and expire October 1, 2036.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
AC Immune SA director Thomas Graney’s amendment is filed solely to add a copy of his Power of Attorney as Exhibit 24. It also lists his direct holdings as of October 2, 2026: 12,959 common shares, including 8,936 common shares underlying outstanding restricted share units, and options covering 19,565 common shares at an exercise price of $2.71. The options are exercisable June 10, 2027, and expire October 1, 2036.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Common Shares F1 | -- | -- | -- |
Footnotes (1)
- F1. Includes 8,936 common shares underlying outstanding restricted share units.
Key Figures
Key Terms
exercise price financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.